• Jobs
  • Startups
  • Hire
LoginSign up

Systimmune

Systimmune has 68 open roles, 23 posted in the last 30 days. Stated pay range: $45k – $500k a year.

Open roles

  • Systimmune logo
    Medical Writer

    Systimmune

    • Princeton, NJ
    • On-site · Senior
    • $80k–$130k
    JazzHR
    Posted today
  • Systimmune logo
    Clinical Development Physician

    Systimmune

    • Princeton, NJ
    • Director / Executive
    • $200k–$300k
    JazzHR
    Posted 2d ago
  • Systimmune logo
    Associate Director, Clinical Project Management - Oncology

    Systimmune

    • Princeton, NJ
    • Hybrid · Director / Executive
    • $150k–$180k
    JazzHR
    Posted 3d ago
  • Systimmune logo
    Manager/Sr. Manager, PV Operation - Oncology Biotech

    Systimmune

    • Princeton, NJ
    • Senior
    JazzHR
    Posted 4d ago
  • Systimmune logo
    Senior Research Associate, Analytical Development

    Systimmune

    • Bothell, WA
    • On-site · Senior
    • $70k–$90k
    JazzHR
    Posted 4d ago
  • Systimmune logo
    HR Business Partner, Bilingual Chinese

    Systimmune

    • Bothell, WA
    • On-site · Mid-level
    • $100k–$150k
    JazzHR
    Posted 7d ago
Show all roles

About

Systimmune logo

Systimmune

Located in Bothell WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

Private company
Founded2014
HQBothell, United States
Size51–200 employees
Unlock human wisdom
ThesisTermsPrivacy
Industry
Biotechnology Research
News
  • BMS, SystImmune Report Phase 3 PFS Data for Iza-Bren in EGFR NSCLC
  • BMS, SystImmune's iza-bren doubles PFS in Phase III lung cancer trial
  • Bristol Myers Squibb and SystImmune Unveil Favorable Phase 3 Results in Lung Cancer
  • BMS and SystImmune's iza-bren doubles progression-free survival in Phase 3 EGFR-mutated lung cancer trial

Claim systimmune.com

Work at systimmune.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.